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To the Editor,
I would like to make few comments on Balcı and 
her colleagues’ paper entitled “Complex cytogenetic 
findings in the bone marrow of a chronic idiopathic 
myelofibrosis patient” which was published in the 
recent issue of the Journal. [1].
Although the authors’ cytogenetic findings looks 
original, it should be considered that chronic idio-
pathic myelofibrosis (CIF) is a colonal disorder like 
chronic myeloid leukemia (CML), polycythemia 
vera, etc.
Among them only Philadelphia chromosome 
(Ph1) is specific for CML, but mutations are present 
in all of these clonal disorders. I believe since the 
cytogenetic changes are not pathognomic or spe-
cific, these kind of studies should be carried only on 
research basis. In addition to radiation as men-
tioned by the authors makes the interpretation of 
their findings more questionable.
On this occasion, I would specifically like to 
emphasize the MDMP treatment for these patients 
which seems to be the only approach in the treat-
ment of this disorder. In addition to some stem cell 
transplantation reports, MDMP is cheap, safe and 
easily applicable in all conditions.
Although we first reported patient with CIF in 
1957 from this country [2], we treated almost a 
dozen of CIF cases without major complications in 
children and adults since 1983 [3-13]. MDMP treat-
ment was mentioned in several occasions in this 
journal, we sorry that despite of its international 
consideration, except ITP treatment,my colleagues 
did not take it seriously [14].
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Reply
Dear Editor,
We read the comments of Dr. Özsoylu about our 
recently published case report titled “Complex cyto-
genetic findings in the bone marrow of a chronic 
idiopathic myelofibrosis patient”. We would like to 
thank Dr. Özsoylu very much for reminding us the 
importance of especially megadose methyl pred-
nisolon for the treatment of different hematologic 
diseases. 
Idiopathic myelofibrosis that is seen in adults is 
an incurable disease without allogeneic stem cell 
transplantation [1,2]. Many kinds of therapies such 
as chemotherapeutics [3,4] including busulfan, 
hydroxyurea, chlorambucil, 2-chlorodeoksiade-
nosamine; biologic response modifier regimens [5]; 
corticosteroids, anabolic steroids [5,6]; thalidomide 
[7, 8], lenalidomide [9] have been used but none of 
them has changed the biology of the disease and 
survival rates of patients [10]. Since there is no opti-
mal therapy, the choice of the drug depends on the 
patient’s characteristics and the physician’s experi-
ence. Hydroxyurea was the drug of choice by the 
doctor who first saw him. When we met the patient, 
he was refractory to that therapy and had a very 
painful large spleen. Because of his comorbid con-
ditions, splenic irradiation had been used to palliate 
his symptoms. The response was transient, as 
expected, and after a short period of time he died 
due to progressive disease.
As we have mentioned in the case report, most 
patients with primary myelofibrosis have karyotypic 
abnormalities at diagnosis and some of them have 
been associated with an adverse prognosis. A cor-
relation between the presence of multiple chromo-
somal deletions and poor survival has been report-
ed [10]. The reason for the development of new 
chromosomal abnormalities in this patient is a dif-
ficult question to answer. As you have mentioned it 
may be the radiation he received or the immuno-
logic stimuli or the chemical agents and/or indus-
trial solvents he had been exposed [10]. Whatever 
the reason, we have shown the abnormality and 
wanted to share this new knowledge with our col-
leagues studying in the same area.
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